This analysis of pancreatitis events in phase III clinical trials and two endpoint trials with GLP-1 receptor agonists did not reveal significant differences between the incretin-based drugs and their comparators
It reads pathway variants like GLP1R and TCF7L2 to describe your baseline metabolism, context to discuss with a provider alongside the clinical decision
The strategy was, therefore, to identify GLP-1 mimetic drugs with a molecular structure close enough to native GLP-1 to stimulate the GLP-1 receptor, but with alterations that enabled prolonged activity by, in particular, possessing resistance to breakdown by DPP-4 (Meier, 2012)
Therapeutic mechanisms of vagus nerve stimulation
As strong supporters of voluntary industry self-regulation and NADs mission of promoting high standards of truth and accuracy, we are committed to evidence-based claims and to periodic review and refinement of our messaging
PMID: 17658628